Financial Engines Advisors L.l.c. Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Financial Engines Advisors L.l.c. reduced its stake in Abbott Laboratories by 13.46% during the most recent quarter end. The investment management company now holds a total of 120,110 shares of Abbott Laboratories which is valued at $5,409,754 after selling 18,680 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Abbott Laboratories makes up approximately 4.33% of Financial Engines Advisors L.l.c.’s portfolio.

Other Hedge Funds, Including , Bryn Mawr Trust Co boosted its stake in ABT in the latest quarter, The investment management firm added 4,450 additional shares and now holds a total of 513,634 shares of Abbott Laboratories which is valued at $23,134,075. Abbott Laboratories makes up approx 1.42% of Bryn Mawr Trust Co’s portfolio.Markston International reduced its stake in ABT by selling 1,175 shares or 1.01% in the most recent quarter. The Hedge Fund company now holds 114,691 shares of ABT which is valued at $5,008,556. Abbott Laboratories makes up approx 0.45% of Markston International’s portfolio.Regentatlantic Capital reduced its stake in ABT by selling 17,759 shares or 23.27% in the most recent quarter. The Hedge Fund company now holds 58,569 shares of ABT which is valued at $2,497,968. Abbott Laboratories makes up approx 0.23% of Regentatlantic Capital’s portfolio.

Abbott Laboratories closed down -0.12 points or -0.27% at $44.24 with 94,39,877 shares getting traded on Friday. Post opening the session at $44.17, the shares hit an intraday low of $43.645 and an intraday high of $44.31 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.